Down 7.2% today, more than its diagnostic peers' 3.4%; no story names it yet.
Fell on Nov 5
Down 54% on Nov 5, a down day for the market: the S&P 500 fell 4%, 86% of stocks fell, and diagnostic stocks a median 5%.
−1Long-term trend
VCYT's Quality Score fell 2 points on Tue, Nov 10, to 6. It closed away from its high of the day (2 chart checks stopped).
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
| The company | Profit up 318% to $127M |
| Latest filing | 10-Q, Nov 5 |
TodayNo story names it yet.
Tue Nov 10: UBS Global Healthcare Conference 2026Investor conference · date confirmed.
2 more dates ahead: conferences, for Pro members.
After its last 4 reports it closed -10.8% on average, higher 2 of 4 times.
VCYT is #12 of 18 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 12 |
Expected to report Wed Feb 24, after the close (in 106 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
Sales of $151.8M, 15% more than a year ago; a profit of $0.38 a share, from $0.24.
“Increased total revenue by 15% to $151.8 million and testing revenue by 15% to $146.4 million, driven by Decipher Prostate growth of 12% to $92.3 million and Afirma growth of 19% to $51.5 million.”
| Line | Q3 2026 | Q2 2026 | Q3 2025 |
|---|---|---|---|
| Testing | $146M | $146M | $128M |
Each quarter's sales and their share of its total. Figures as filed (SEC filing, Nov 5)
| Measure | Figure |
|---|---|
| Total revenue | $590M to $593M |
“Increased product revenue by 40% to $4.6 million, driven by strong adoption of Prosigna IVD following the release of the phase III OPTIMA trial results at ASCO.”
From its results filing (SEC filing · Nov 4)
Sales grew 35% a year over 5 years, fiscal 2020 to 2025.
Its share count grew 8.6% a year over 5 years.
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Nov 4, 2026 | -43.7% | -54.3% | not yet |
| Jul 30, 2026 | -18.4% | -22.5% | -22.8% |
| May 5, 2026 | +18.3% | +24.9% | +20.0% |
Sales grew in six of the last seven years, to $517M in 2025. It made a profit in two of the eight years.
RSI 26.7, MACD below signal, below both averages. Not scored.
One insider sold $1.1M across 1 filing in the last 6 months. No open-market buys on record. The newest:
One trade disclosed in the last six months. The newest:
Officers and directors with a Form 4 in the last 12 months.
In ETFs: VCYT is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder).
“Our main competition are companies that use next generation sequencing technology or other methods to measure genomic biomarkers in disease areas addressed by our tests.”
VCYT scores 6 today, which Breakaway calls Average. It is #12 of 18 in Services-Medical Laboratories by Quality Score, with 2 of 14 chart checks firing. Down 54% on Nov 5, a down day for the market: the S&P 500 fell 4%, 86% of stocks fell, and diagnostic stocks a median 5%. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
VCYT scores 6 today, which Breakaway calls Average (6 to 10). That is #12 of 18 in Services-Medical Laboratories by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind VCYT's 6.
One insider sold $1.1M across 1 filing in the last 6 months. No open-market buys on record. The newest is Jonathan Wygant, VP, Chief Accounting Officer, who sold $1.1M on May 22.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free until Thursday morning. No account. No card. Then keep going with a free account.